Research Analysts’ Recent Ratings Updates for Incyte (INCY)

by · The Markets Daily

Incyte (NASDAQ: INCY) has recently received a number of price target changes and ratings updates:

  • 11/10/2025 – Incyte was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
  • 11/4/2025 – Incyte had its price target raised by analysts at Piper Sandler from $82.00 to $102.00. They now have an “overweight” rating on the stock.
  • 11/3/2025 – Incyte was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $125.00 price target on the stock.
  • 11/1/2025 – Incyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
  • 10/29/2025 – Incyte had its price target raised by analysts at Royal Bank Of Canada from $81.00 to $84.00. They now have a “sector perform” rating on the stock.
  • 10/29/2025 – Incyte had its price target raised by analysts at Wells Fargo & Company from $89.00 to $97.00. They now have an “overweight” rating on the stock.
  • 10/29/2025 – Incyte had its price target raised by analysts at Barclays PLC from $90.00 to $101.00. They now have an “overweight” rating on the stock.
  • 10/29/2025 – Incyte had its “hold” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $93.00 price target on the stock, up previously from $79.00.
  • 10/18/2025 – Incyte was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
  • 10/10/2025 – Incyte was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
  • 10/9/2025 – Incyte had its price target raised by analysts at JPMorgan Chase & Co. from $73.00 to $89.00. They now have a “neutral” rating on the stock.
  • 10/8/2025 – Incyte was downgraded by analysts at Oppenheimer Holdings, Inc. from an “outperform” rating to a “market perform” rating.
  • 10/8/2025 – Incyte had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
  • 10/3/2025 – Incyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
  • 9/27/2025 – Incyte had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
  • 9/24/2025 – Incyte had its price target raised by analysts at Royal Bank Of Canada from $72.00 to $81.00. They now have a “sector perform” rating on the stock.
  • 9/22/2025 – Incyte had its price target raised by analysts at Stifel Nicolaus from $110.00 to $115.00. They now have a “buy” rating on the stock.
  • 9/19/2025 – Incyte had its “neutral” rating reaffirmed by analysts at Guggenheim.

Insider Buying and Selling at Incyte

In related news, EVP Sheila A. Denton sold 598 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $101.36, for a total value of $60,613.28. Following the transaction, the executive vice president owned 26,569 shares in the company, valued at $2,693,033.84. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Lee Heeson sold 3,074 shares of Incyte stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $94.02, for a total value of $289,017.48. Following the completion of the sale, the executive vice president owned 29,241 shares of the company’s stock, valued at approximately $2,749,238.82. The trade was a 9.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 4,227 shares of company stock valued at $396,327 over the last three months. Insiders own 17.80% of the company’s stock.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

See Also